Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: A reevaluation in East Asian populations

[1]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  R. Yoshimura,et al.  An evaluation of polymorphisms in casein kinase 1 delta and epsilon genes in major psychiatric disorders , 2012, Neuroscience Letters.

[3]  R. Yoshimura,et al.  Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients , 2012, International journal of psychiatry in clinical practice.

[4]  R. Yoshimura,et al.  Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[5]  E. Kornetova,et al.  Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[7]  Y. Liou,et al.  Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in chinese schizophrenic patients , 2007, NeuroMolecular Medicine.

[8]  R. Baldessarini,et al.  Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? , 2006, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. Os,et al.  Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis , 2006, Schizophrenia Research.

[10]  T. Shinkai,et al.  Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia , 2006, Psychiatry Research.

[11]  B. Lerer,et al.  Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms , 2006, Pharmacogenetics and genomics.

[12]  J. Lieberman,et al.  Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial , 2005, Schizophrenia Research.

[13]  B. Lerer,et al.  Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms , 2005, Schizophrenia Research.

[14]  P. Sachdev.  Neuroleptic-induced movement disorders: an overview. , 2005, The Psychiatric clinics of North America.

[15]  K. Svensson,et al.  Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain , 2005, Journal of Neural Transmission / General Section JNT.

[16]  T. Shinkai,et al.  Clinical implications of pharmacogenomics for tardive dyskinesia , 2004, The Pharmacogenomics Journal.

[17]  G. Reynolds,et al.  Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia , 2003, Psychiatric genetics.

[18]  E. Tan,et al.  Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[19]  Chul-Soo Park,et al.  Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics , 2002, Psychiatry and clinical neurosciences.

[20]  B. Lerer.  Pharmacogenetics of psychotropic drugs , 2002 .

[21]  S. Tsai,et al.  Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients , 2001, Neuropsychobiology.

[22]  W. Tang,et al.  Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients , 2001, Journal of Neural Transmission.

[23]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[24]  Fabio Macciardi,et al.  Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia , 1999, Neuropsychopharmacology.

[25]  B. Lerer,et al.  Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia , 1999, Molecular Psychiatry.

[26]  T. Terao,et al.  Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics , 1998, Schizophrenia Research.

[27]  P. Sokoloff,et al.  D3 dopamine receptor mRNA is widely expressed in the human brain , 1998, Brain Research.

[28]  V. Steen,et al.  Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients , 1997, Molecular Psychiatry.

[29]  M. P. Turpin,et al.  Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. , 1996, Biochemical and biophysical research communications.

[30]  C. Gerfen,et al.  A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Jane S. Paulsen,et al.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. , 1995, Archives of general psychiatry.

[32]  M. Asai,et al.  Dopamine D3 receptor gene polymorphism and the psychiatric symptoms seen in first‐break schizophrenic patients , 1995, Psychiatric genetics.

[33]  H. Meltzer.  Serotonin2A receptors in schizophrenia: relation to suicide. , 1994, Archives of general psychiatry.

[34]  J. Doucette,et al.  Race and tardive dyskinesia among outpatients at a CMHC. , 1994, Hospital & community psychiatry.

[35]  M. Martres,et al.  Dopamine D3 receptor: basic and clinical aspects. , 1993, Clinical neuropharmacology.

[36]  M. Martres,et al.  Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders , 1992 .

[37]  D. Jeste,et al.  Gender differences in tardive dyskinesia: a critical review of the literature. , 1992, Schizophrenia bulletin.

[38]  S. Hauser,et al.  A simple method for DNA purification from peripheral blood. , 1988, Analytical biochemistry.

[39]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[40]  J. Kane,et al.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 , 1982, Archives of general psychiatry.

[41]  J. Gerlach,et al.  γ-Acetylenic GABA in Tardive Dyskinesia , 1980 .

[42]  R. Baldessarini,et al.  Changes in prevalence, severity, and recovery in tardive dyskinesia with age. , 1980, Archives of general psychiatry.

[43]  R. Baldessarini,et al.  Pathophysiologic basis of tardive dyskinesia. , 1977, Advances in biochemical psychopharmacology.